These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 2484073

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW, Nicolini FA, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):231-6. PubMed ID: 1717784
    [Abstract] [Full Text] [Related]

  • 3. Peptide 6A, a fibrin(ogen) degradation product, increases coronary blood flow.
    Mehta J, Wargovich T, Nichols WW, Saldeen K, Wallin R, Saldeen T.
    Am J Physiol; 1985 Sep; 249(3 Pt 2):H457-62. PubMed ID: 3839977
    [Abstract] [Full Text] [Related]

  • 4. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF.
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [Abstract] [Full Text] [Related]

  • 5. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 6. Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs.
    Saldeen K, Nichols W, Lawson D, Andersson R, Saldeen T, Mehta J.
    Acta Physiol Scand; 1991 Jul; 142(3):339-44. PubMed ID: 1656701
    [Abstract] [Full Text] [Related]

  • 7. Replacement of L-Lys by D-Lys(NH2) in peptide Ala-Arg-Pro-Ala-Lys (peptide 6A) increases its coronary blood flow-promoting properties.
    Saldeen TG, Nichols WW, Saldeen K, Wallin R, Mehta JL.
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):103-6. PubMed ID: 7511720
    [Abstract] [Full Text] [Related]

  • 8. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

  • 9. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 10. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 11. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 12. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 14. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY, Nichols WW, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [Abstract] [Full Text] [Related]

  • 15. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 16. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 17. Fibrin(ogen)-derived peptide B beta 30-43 increases coronary blood flow in the anesthetized dog.
    Nichols WW, Mehta J, Wargovich T, Saldeen K, Wallin R, Saldeen T.
    Thromb Res; 1985 Jul 15; 39(2):223-9. PubMed ID: 3895564
    [Abstract] [Full Text] [Related]

  • 18. Thrombolytic effects of intracoronary streptokinase on canine coronary artery thrombosis.
    Fiedler VB.
    Basic Res Cardiol; 1984 Jul 15; 79(1):17-26. PubMed ID: 6732717
    [Abstract] [Full Text] [Related]

  • 19. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1991 May 15; 17(5):738-46. PubMed ID: 1713988
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.